Kumquat Biosciences Inc. has identified GTPase KRAS and KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer, particularly solid tumors and hematological cancer.
Gibson Oncology LLC and Purdue Research Foundation have synthesized DNA topoisomerase I (Topo1) inhibitors and/or Myc proto-oncogene protein promoter G-quadruplex (MycG4) ligands reported to be useful for the treatment of cancer.
Most patients with non-small-cell lung cancer (NSCLC) develop acquired drug resistance to EGFR inhibitors. Osimertinib, a third-generation inhibitor, often sees its therapeutic effect reduced due to the C797S mutation of EGFR exon 20, which blocks the binding of Cys797 to osimertinib.
Phenomic AI Inc. has announced new collaboration agreements to help advance drug discovery for stroma-rich tumors using its Sctx single-cell transcriptomics platform.
Researchers from Multitude Therapeutics Inc. have reported the preclinical profile of AMT-253, a MUC18-targeting antibody-drug conjugate (ADC) under development for the treatment of melanoma. It comprises the anti-MUC18 humanized antibody pAb253-H linked to T1000 exatecan payload and showed superior antitumor efficacy than the traditional vc-MMAE-based ADC AMT-253-M.
Researchers at Dana-Farber Cancer Institute are advancing a fourth-generation allosteric EGFR inhibitor, EAI-432, to treat non-small-cell lung cancer driven by mutations in the EGFR gene, particularly the L858R mutation.
Proteoglycan glypican-1 (GPC1) is a tumor-associated antigen that is highly expressed in tumor tissues from patients with pancreatic ductal adenocarcinoma (PDAC), while its expression is very low on benign neoplastic lesions, chronic pancreatitis and normal adult pancreatic tissue. Researchers from Centro Di Riferimento Oncologico (CRO Aviano) and L'Università degli studi di Trieste have reported the development and preclinical characterization of AT-101, a novel complement-fixing IgM antibody targeting GPC1, as a potential immunotherapy candidate for the treatment of PDAC.
Patients with end-stage pancreatic ductal adenocarcinoma achieved unprecedented survival rates after being treated with the Engeneic dream vector nanocells, with 88% of patients doubling the historical survival rates, Engeneic Ltd. co-CEO Jennifer MacDiarmid told BioWorld.
RSS
.webp?height=488&t=1677877909&width=650 "Epidermal growth factor receptor (EGFR)")